n the materials that can be broken down by the body and that do not require mechanical removal, such as sutures or the chlorhexidine chip.
References in periodicals archive ?
Key endpoints of the study include assessments of safety - MACE and treated site thrombosis rates - at 30 days; six, nine, 12, 18 and 24 months; with additional annual clinical follow-up for up to five years, as well as an assessment of the acute performance of the bioresorbable vascular scaffold, including successful deployment of the system.
Serica Technologies today reported first data on the use of a non-mammalian derived silk-based long-term bioresorbable implant for rotator cuff tendon (RCT) repair, which demonstrated potential to reduce primary repair failure following surgery, in an animal model.
PARIS -- Arterial Remodeling Technologies ("ART") reported today that in vivo data strongly suggest that its next-generation bioresorbable stent promotes positive arterial remodeling in a post-angioplasty porcine model at six months follow-up.
is developing a bioresorbable coronary scaffold for cardiovascular disease.
The market is divided into 5 segment modalities, including transcatheter heart valves, renal denervation, bronchial thermoplasty, bioresorbable stents, and fractional flow reserve.
First-of-its-Kind Drug Eluting Bioresorbable Vascular Scaffold Now Being Evaluated in U.
GLOBAL pharma giant Abbott launched the bioresorbable vascular scaffold in India on Wednesday.
Abbott (NYSE: ABT) has announced the initiation of ABSORB II, the first randomized, controlled, multi-center clinical trial to evaluate the safety, efficacy and performance of the Absorb bioresorbable vascular scaffold (BVS) compared to the company's XIENCE PRIME Everolimus Eluting Coronary Stent System.
Stryker Neuro Spine ENT continues to focus on its commitment to provide the most innovative and effective products for ENT surgeons with the addition of Nasopore, a bioresorbable nasal dressing for use as a sinus stent.
Food & Drug Administration) has granted 510(k) clearance for its new bioresorbable polymer-coated surgical mesh product for the repair of hernias and other abdominal fascial or muscular deficiencies requiring the addition of a reinforcing or bridging material.
San Diego, CA, announced it has completed the 20-patient, 12-month clinical evaluation of the new Faster Resorbing Polymer (FRP) bioresorbable implant system required for a $5 million payment related to the sale of the Craniomaxillofacial/Neurosurgical (CMF/N) business unit to Medtronic, Inc.
A bioresorbable product that shields the nerve while allowing regeneration would afford improved outcomes in this difficult situation.